News Column

BIAL And moksha8 Announce Exclusive License For The Commercialization Of Eslicarbazepine Acetate Zebinix® / Exalief® In Brazil And Mexico

July 30, 2014

By a News Reporter-Staff News Editor at Biotech Week -- BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Latin America, announced an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix® / (Exalief®) in Brazil and Mexico for the treatment of epilepsy (see also moksha8).

Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in Latin America - and the successful treatment of partial-onset seizures (the most common type of epilepsy) remains a challenge. Up to 40% of patients with partial seizures do not achieve sustained seizure control with current treatments (1).?There are many patients with epilepsy whose condition is difficult to treat with existing anti-epileptic drugs. Eslicarbazepine acetate ® is an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalization (where the seizure spreads to both sides of the brain).

"moksha8 is committed to providing the highest quality products to physicians and patients to improve the treatment of critical CNS indications," said Simba Gill, CEO of moksha8. "Epilepsy is a serious condition that not only affects the people who suffer from seizures, but also their family, caregivers and friends. We look forward to bringing eslicarbazepine acetate to Brazil and Mexico."

"Eslicarbazepine acetate developed by BIAL is the outcome of BIAL's longstanding scientific commitment to CNS research and development and the desire to improve the quality of life in those patients with poor seizure control," commented Antonio Portela, CEO of BIAL. "We are pleased to be working with moksha8 in Brazil and Mexico as a high quality partner in two of the largest markets in Latin America."

The Latin America retail pharmaceutical market is estimated by IMS at USD $68 billion in 2013, growing at 12% CAGR to over USD $110 billion by 2017. Brazil is expected to be the fourth largest pharmaceutical market in the world by 2017.

Eslicarbazepine acetate was approved by the European Commission in 2009 based on data showing that it reduces seizure frequency and improves health-related quality of life and is commercialized in the European Union under the trade name Zebinix®. Eslicarbazepine acetate was approved by the U.S., Food and Drug Administration (FDA), in November 2013 and is sold in the U.S. under the trade name APTIOM®. Eslicarbazepine acetate does not yet have a marketing authorization in Brazil or Mexico.

About epilepsy, partial-onset seizures and their treatment Epilepsy is a chronic neurological disease characterized by abnormal discharges of neuronal activity causing seizures. Clinically, these manifest as convulsions or jerking of muscles. Depending on the seizure type, seizures may be limited to one part of the body, or may be generalized to involve the whole body. Patients may also experience abnormal sensations, altered behaviour or altered consciousness. Epilepsy is a disorder with many possible causes. Often the cause of epilepsy is unknown. However, anything that disturbs the normal pattern of neuron activity - from illness to brain damage to abnormal brain development, can lead to seizures.

Epilepsy is characterised by abnormal firing of impulses from nerve cells in the brain. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more generalised; the symptoms vary according to the affected areas. Nerve impulses are triggered via voltage-gated sodium channels in the nerve cell membrane.

Treatment of partial-onset seizures, the most common type of epilepsy, presents a constant challenge - up to 40% of patients with partial-onset seizures do not achieve sustained seizure control with current anti-epileptic drugs(1). Furthermore, central nervous system related adverse events, such as lightheadedness (dizziness), somnolence (sleepiness), and cognitive slowing (attention and memory deficits), are highly prevalent with existing anti-epileptic agents. Hence, there is a need for new anti-epileptic agents that offer effective reduction in seizure frequency combined with a favourable safety profile.

About eslicarbazepine acetate (Zebinix® / Exalief®) Eslicarbazepine acetate is a once-daily, voltage-gated sodium channel blocker. It preferentially targets the inactivated state of the ion channel, preventing its return to the active state, and thereby reduces repetitive neuronal firing (2-4).

Keywords for this news article include: Central Nervous System, Epilepsy, Marketing and Licensing Agreements, Neurologic Manifestations, Seizures, moksha8.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters